INDICATIONS AND USAGE

XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines with corrugator and/or procerus muscle activity in adult patients.

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT
See full prescribing information for complete BOXED WARNING.

The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

Please see Important Safety Information throughout and accompanying Full Prescribing Information, including BOXED WARNING.

XEOMIN® incobotulinumtoxinA

XPERTLY DESIGNED

Purity and stability

XEOMIN is the only clinically proven anti-wrinkle injection uniquely purified to remove unnecessary proteins.*

- XTRACT Technology™ is the only state-of-the-art manufacturing process that uniquely purifies the molecule, removing the unnecessary proteins and leaving just the active therapeutic component*[1-3]
- XEOMIN is the **only neurotoxin** that can be shipped and stored at room temperature prior to reconstitution[4]

*The direct impact of the non-therapeutic proteins on long-term safety or efficacy has not been established. Information about the unique XEOMIN manufacturing process and the properties of incobotulinumtoxinA is not intended to imply superiority over other botulinum toxin type A products.



Botulinum toxin type A is produced from Hall strain *Clostridium botulinum* Serotype A1

Unnecessary proteins are separated by chromatography, producing a purified molecule

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN should be discontinued and appropriate medical therapy immediately instituted. XEOMIN is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.
- Use in patients with an infection at the injection site could lead to severe local or disseminated infection. XEOMIN is contraindicated in the presence of infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS

- The potency units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN can-not be compared to or converted into Units of any other botulinum toxin products.
- Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [*See BOXED WARNING*].

Please see Important Safety Information throughout and accompanying Full Prescribing Information, including BOXED WARNING.

XPERIENCE THAT COUNTS

With nearly 15 years of clinical and global experience, XEOMIN has a well-established efficacy and safety profile

In 2 randomized, double-blind, multicenter clinical trials, XEOMIN was proven to temporarily improve the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.[4-6]

BEFORE **AFTER**

"After" photo taken 30 days after injection. Individual results may vary. Unretouched photos taken at maximum frown.

SIGNIFICANTLY SUPERIOR EFFICACY OVER PLACEBO[4-6]



Patients were injected with a total of 20 units, 5 injection points in the glabellar (547 patients).[4-6]

≥2
POINT IMPROVEMENT
agreed upon by patient and physician on a 4-point scale[4-6]

UP TO
4
MONTHS
of XEOMIN efficacy and patient satisfaction in a majority of patients[7,8]

MORE THAN
90%
patient satisfaction[7]

WARNINGS AND PRECAUTIONS (CONTINUED)

- Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN.
- **Glabellar Lines:** Do not exceed the recommended dosage and frequency of administration of XEOMIN. In order to reduce the complication of ptosis the following steps should be taken:
  - avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes;
  - corrugator injections should be placed at least 1 cm above the bony supraorbital ridge.
- XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and Creutzfeldt-Jakob disease (CJD). No cases of transmission of viral diseases or CJD have ever been reported for albumin.

XEOMIN® incobotulinumtoxinA

XTRAORDINARY COMMITMENT

Merz is a family-owned company dedicated to neurotoxins and aesthetics, with programs designed to help support your practice

Virtual Xperience Program = Patient Savings

- $50 instant offer per treatment, up to 4 times per year
- Simple and easy program for practices to use
- 88% of Virtual Xperience Program™ patients would recommend XEOMIN to a friend[7]

UP TO

$200

in patient savings per year

VIRTUAL XPERIENCE™ PROGRAM

Check out www.xeominaesthetic.com/professionals/xperience-program to learn more.

Follow us on Instagram! @XEOMINAESTHETIC

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS

Glabellar Lines: The most commonly observed adverse reaction (incidence ≥2% of patients and greater than placebo) for XEOMIN was Headache (5.4%).

DRUG INTERACTIONS

Co-administration of XEOMIN and aminoglycoside antibiotics or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.

Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects. The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

USE IN PREGNANCY

There are no adequate data on the developmental risk associated with the use XEOMIN in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

Safety and effectiveness of XEOMIN in patients less than 18 years of age have not been established.

References: 1. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. *Drugs R D*. 2015;15:1-9. **2.** Data on file, Merz North America. **3.** Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin): the first botulinum toxin drug free of complexing proteins. *Eur J Neurol*. 2012;19(3):385-389. **4.** XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use. Prescribing Information. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019. **5.** Hanke CW, Narins RS, Brandt F, et al. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. *Dermatol Surg*. 2013;39(6):891-899. **6.** Carruthers A, Carruthers J, Heinz M, et al. Multicentre, randomized phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. *Dermatol Surg*. 2013;39:551-558. **7.** Data on file, Merz North America. **8.** Kane MA, et al. A randomized, double-blind trial to investigate the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. *Dermatol Surg*. 2015;41(11):1310-1319.

Please see Important Safety Information throughout and accompanying Full Prescribing Information, including BOXED WARNING.

MERZ AESTHETICS®

XEOMIN® incobotulinumtoxinA